A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
Public ClinicalTrials.gov record NCT06192108. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-2)
Study identification
- NCT ID
- NCT06192108
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Eli Lilly and Company
- Industry
- Enrollment
- 962 participants
Conditions and interventions
Conditions
Interventions
- Dapagliflozin Drug
- Orforglipron Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 9, 2024
- Primary completion
- Sep 25, 2025
- Completion
- Sep 25, 2025
- Last update posted
- Oct 19, 2025
2024 – 2025
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alliance Research Institute - Canoga Park | Canoga Park | California | 91304 | — |
| Ark Clinical Research | Long Beach | California | 90815 | — |
| Collaborative Neuroscience Research, LLC | Los Alamitos | California | 90720 | — |
| Wolverine Clinical Trials | Santa Ana | California | 92706 | — |
| CMR of Greater New Haven, LLC | Hamden | Connecticut | 06517 | — |
| Institute of Endocrinology Diabetes, Health & Hormone | Stockbridge | Georgia | 30281 | — |
| Elite Clinical Trials | Rexburg | Idaho | 83440 | — |
| Accellacare - DuPage | Lombard | Illinois | 60148 | — |
| Tandem Clinical Research | Marrero | Louisiana | 70072 | — |
| St. Vincent Healthcare | Billings | Montana | 59101 | — |
| Albuquerque Clinical Trials, Inc. | Albuquerque | New Mexico | 87102 | — |
| Accellacare - Winston-Salem | Winston-Salem | North Carolina | 27103 | — |
| Alliance for Multispecialty Research, LLC | Norman | Oklahoma | 73069 | — |
| Essential Medical Research | Tulsa | Oklahoma | 74137 | — |
| Accellacare - Mt Pleasant | Mt. Pleasant | South Carolina | 29464 | — |
| Accellacare, US Inc., d/b/a Accellacare of Knoxville | Jefferson City | Tennessee | 37760 | — |
| Velocity Clinical Research, Dallas | Dallas | Texas | 75230 | — |
| Juno Research | Houston | Texas | 77040 | — |
| Consano Clinical Research, LLC | Shavano Park | Texas | 78231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06192108, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 19, 2025 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06192108 live on ClinicalTrials.gov.